Preβ1-high-density lipoprotein binds to TG-rich lipoproteins and its release is impaired in the postprandial state among patients with poorly controlled type 2 diabetes

Abstract

Background

Although preβ1-high-density lipoprotein (preβ1-HDL) promotes cholesterol efflux, high fasting preβ1-high-density lipoprotein levels after breakfast are reduced in patients with poorly controlled type 2 diabetes.

Objective

This study investigated whether preβ1-high-density lipoprotein binds to triglyceride (TG)-rich lipoproteins (TGRLs) in the postprandial state and is released during lipolysis.

Methods

We measured preβ1-high-density lipoprotein concentrations, lecithin-cholesterol acyltransferase (LCAT) activity, and LCAT-dependent preβ1-high-density lipoprotein conversion before and after breakfast in patients with diabetes. We also performed in vitro studies using TGRLs. Preβ1-high-density lipoprotein was quantified by enzyme-linked immunosorbent assay and native two-dimensional gradient gel (N-2D-gel) electrophoresis.

Results

Before breakfast, the diabetes group had higher preβ1-high-density lipoprotein concentrations than the healthy controls; after breakfast, levels in the two groups were similar. Neither LCAT mass nor the LCAT-dependent preβ1-high-density lipoprotein conversion rate changed after breakfast. Mixing of fasting plasma with chylomicrons or very-low-density lipoprotein (VLDL) reduced the preβ1-high-density lipoprotein level by 15% ± 4% and 45% ± 10%, respectively. N-2D-gel electrophoresis showed that preβ1-high-density lipoprotein was generated by bacteria-derived TG lipase only from postprandial VLDL of patients with type 2 diabetes.

Conclusion

Preβ1-high-density lipoprotein binds to TGRLs in the postprandial state and is released during lipolysis, implying that postprandial hyperlipidemia impairs reverse cholesterol transport in patients with poorly controlled type 2 diabetes.

Keywords

Apolipoprotein AI postprandial hyperlipidemia high-density lipoprotein subfraction lecithin-cholesterol acyltransferase preβ1-high-density lipoprotein diabetes mellitus triglyceride-rich lipoproteins

Get full access to this article

View all access options for this article.

References

Charvat

Goto

, et al. Impact of population aging on trends in diabetes prevalence: a meta-regression analysis of 160,000 Japanese adults. J Diabetes Investig 2015; 6(5): 533–542.

Rawshani

Franzen

, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 2017; 376(15): 1407–1418.

Hamada

Gulliford

. Multiple risk factor control, mortality and cardiovascular events in type 2 diabetes and chronic kidney disease: a population-based cohort study. BMJ Open 2018; 8(5): e019950.

Sunil

Ashraf

. Dyslipidemia in pediatric type 2 diabetes mellitus. Curr Diab Rep 2020; 20(10): 53.

Kinoshita

Yokote

Arai

, et al. Japan atherosclerosis society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb 2018; 25(9): 846–984.

Boden

Probstfield

Anderson

, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365(24): 2255–2267.

Landray

Haynes

Hopewell

, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014; 371(3): 203–212.

Tall

Rader

. Trials and tribulations of CETP inhibitors. Circ Res 2018; 122(1): 106–112.

Horiuchi

Ohkawa

Lai

, et al. Usefulness of apolipoprotein B-depleted serum in cholesterol efflux capacity assays using immobilized liposome-bound gel beads. Biosci Rep 2019; 39(4): BSR20190213.

10.

Yokoyama

. Assembly of high-density lipoprotein. Arterioscler Thromb Vasc Biol 2006; 26(1): 20–27.

11.

Kawano

Miida

Fielding

, et al. Quantitation of pre beta-HDL-dependent and nonspecific components of the total efflux of cellular cholesterol and phospholipid. Biochemistry 1993; 32(19): 5025–5028.

12.

Miida

Kawano

Fielding

, et al. Regulation of the concentration of pre beta high-density lipoprotein in normal plasma by cell membranes and lecithin-cholesterol acyltransferase activity. Biochemistry 1992; 31(45): 11112.

13.

Hirayama

Miida

Miyazaki

, et al. Pre beta1-HDL concentration is a predictor of carotid atherosclerosis in type 2 diabetic patients. Diabetes Care 2007; 30(5): 1289–1291.

14.

Hirayama

Ito

Miyazaki

, et al. Prebeta1-HDL is elevated in the fasting state, but markedly reduced postprandially in poorly controlled type 2 diabetic patients. Clin Chim Acta 2009; 401(1-2): 57–62.

15.

Araki

Goto

Kondo

, et al. Japanese clinical practice guideline for diabetes 2019. Diabetol Int 2020; 11(3): 165–223.

16.

Miida

Nakamura

Inano

, et al. Pre beta 1-high-density lipoprotein increases in coronary artery disease. Clin Chem 1996; 42(12): 1992–1995.

17.

Miida

Miyazaki

Hanyu

, et al. LCAT-dependent conversion of prebeta1-HDL into alpha-migrating HDL is severely delayed in hemodialysis patients. J Am Soc Nephrol 2003; 14(3): 732–738.

18.

Miida

Nishimura

Okamura

, et al. Validation of homogeneous assays for HDL-cholesterol using fresh samples from healthy and diseased subjects. Atherosclerosis 2014; 233(1): 253–259.

19.

Miida

Nishimura

Hirayama

, et al. Homogeneous assays for LDL-C and HDL-C are reliable in both the postprandial and fasting state. J Atheroscler Thromb 2017; 24(6): 583–599.

20.

Kobori

Saito

Ito

, et al. A new enzyme-linked immunosorbent assay with two monoclonal antibodies to specific epitopes measures human lecithin-cholesterol acyltransferase. J Lipid Res 2002; 43(2): 325–334.

21.

Miyazaki

Kobayashi

Fukamachi

, et al. A new sandwich enzyme immunoassay for measurement of plasma pre-beta1-HDL levels. J Lipid Res 2000; 41(12): 2083–2088.

22.

Miida

Obayashi

Seino

, et al. LCAT-dependent conversion rate is a determinant of plasma prebeta1-HDL concentration in healthy Japanese. Clin Chim Acta 2004; 350(1-2): 107–114.

23.

Yamatani

Hirayama

Seino

, et al. Preβ1-high-density lipoprotein metabolism is delayed in patients with chronic kidney disease not on hemodialysis. J Clin Lipidol 2020; 14(5): 730–739.

24.

Miida

Sakai

Ozaki

, et al. Bezafibrate increases prebeta 1-HDL at the expense of HDL2b in hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2000; 20: 2428–2433.

25.

Neary

Bhatnagar

Durrington

, et al. An investigation of the role of lecithin:cholesterol acyltransferase and triglyceride-rich lipoproteins in the metabolism of pre-beta high density lipoproteins. Atherosclerosis 1991; 89(1): 35–48.

26.

Miyazaki

Fukamachi

Mori

, et al. Formation of prebeta1-HDL during lipolysis of triglyceride-rich lipoprotein. Biochem Biophys Res Commun 2009; 379(1): 55–59.

27.

Nagao

Hirayama

Kon

, et al. Current smokers with hyperlipidemia lack elevated preβ1-high-density lipoprotein concentrations. J Clin Lipidol 2017; 11(1): 242–249.

28.

Sethi

Sampson

Warnick

, et al. High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin Chem 2010; 56(7): 1128–1137.

29.

Guey

Pullinger

Ishida

, et al. Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease. Am J Cardiol 2011; 108(3): 360–366.

30.

Riemens

van Tol

Sluiter

, et al. Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 1998; 140(1): 71–79.

31.

Pan

Shilian

Ishida

, et al. Effect of niacin on preβ-1 high-density lipoprotein levels in diabetes. Metabolism 2011; 60(2): 292–297.

32.

Shiu

Wong

Tan

. Pre-β1 HDL in type 2 diabetes mellitus. Atherosclerosis 2017; 263: 24–28.

33.

Stock

Ferrara

O'Connor

, et al. Levels of prebeta-1 high-density lipoprotein are elevated in 3 phenotypes of dyslipidemia. J Clin Lipidol 2018; 12(1): 99–109.

34.

Asztalos

Le Maulf

Dallal

, et al. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. Am J Cardiol 2007; 99(5): 681–685.

35.

Kawano

Nagasaka

Yagyu

, et al. Pitavastatin decreases plasma prebeta1-HDL concentration and might promote its disappearance rate in hypercholesterolemic patients. J Atheroscler Thromb 2008; 15(1): 41–46.

36.

Quinn

Schwemberger

Stock

, et al. Moderate statin treatment reduces prebeta-1 high-density lipoprotein levels in dyslipidemic patients. J Clin Lipidol 2017; 11(4): 908–1114.